ROVI will release its three-month period ended 31 March 2024 Financial Results on the 8th of May, before...
Investor's Calendar
| Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|
|
25
|
26
|
27
|
28
|
29
|
30
|
1
|
|
|
|
|
|
|
|
|
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
|
|
|
|
|
|
|
|
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
|
|
|
|
|
|
|
|
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
|
|
|
|
|
|
|
|
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
|
|
|
|
|
|
|
|
|
30
|
31
|
1
|
2
|
3
|
4
|
5
|
|
|
|
|
|
|
|
|
Next Events
-
May, 08 2024
Last News
Agreement to manufacture pre-filled syringes for a global pharmaceutical company
3 min
25 Apr, 2024
Risperidone ISM® is a prolonged-release injectable antipsychotic developed and patented by ROVI for the...
4 min
02 Apr, 2024
This public-private collaboration instrument falls within the framework of the Vanguard Health Strategic...
3 min
12 Mar, 2024
Public statements sent to CNMV
ESG
Discover what ROVI is doing to become a more sustainable company
CORPORATE GOVERNANCE
Find out more about ROVI’s main governing bodies
Information for investors
Marta Campos
Head of Investor Relations
Antonio Marquina
Investor Relations
